Androgenetic Alopecia Clinical Trial
— REBOOT-MENOfficial title:
Hair Regrowth Efficacy of Multi-Molecular Targeting Treatment (ALRV5XR), a Randomized Controlled Clinical Trial in Men With Androgenetic Alopecia, Telogen Effluvium or Self Reported Thinning Hair: THE HAIR REBOOT TRIAL - MEN
Verified date | June 2020 |
Source | Arbor Life Labs |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To demonstrate that the ALRV5XR multi-molecular targeting treatment regimen of a daily
shampoo, conditioner, topical serum and oral supplement is superior to placebo in promoting
hair growth as assessed by change in hair density and percentage of terminal hair regrowth
after ALRV5XR therapy.
This will be a single-centre, double-blind, randomized, placebo-controlled study in male
subjects randomized to a 1:1 ratio of test article to placebo.
Subjects will be asked to use the study products on a daily basis for the duration of the
24-week study. Subjects will take one capsule twice daily (one in the morning and one in the
evening) and will be asked to use 3-7mL of the shampoo, 3-7mL of the conditioner, and 1mL of
the topical nutriment daily. Subjects will receive detailed instructions regarding the order
and duration of application of each product.
Subjects in the active arm will receive active capsules, shampoo, conditioner and topical
nutriment. Subjects on placebo will receive placebo capsules, shampoo, conditioner and
topical nutriment. All subjects will be instructed to take the capsules orally, one in the
morning and one in the evening, prior to consuming food. Shampoo and conditioner are to be
used once per day when washing the hair and nutriment applied at the end of the day prior to
bedtime. To facilitate this, subjects will receive a 3-month supply of each product
(supplement, shampoo, conditioner, and scalp nutriment). Subjects will continue the daily
regimen for 24 weeks, visiting the clinic at week 12 for an interim assessment.
Status | Completed |
Enrollment | 46 |
Est. completion date | October 23, 2018 |
Est. primary completion date | October 23, 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Men 18 - 65 years of age at time of screening (V1) (inclusive). 2. Have androgenetic alopecia, diffuse hair loss or self-reported thinning or hair loss for more than 3 months prior to screening (V1). 3. Clinically confirmed to have hair loss or thinning by the investigator via physical exam. 4. In good general health, as determined by the Investigator. 5. Willing and able to attend all study visits. 6. Willing to maintain the same hair style as at the Screening Visit and refrain from chemical treatments on the hair for the duration of the study. 7. Have Fitzpatrick skin type I-IV. 8. Be willing and able to cooperate with the requirements of the study. 9. Willingness to be photographed and provide consent for photographic release. 10. Voluntarily sign and date an informed consent approved by the Institutional Review Board. 11. Be able to complete and understand the various rating instruments in English. 12. Sponsor approved global image assessment of degree of thinning / hair loss. Exclusion Criteria: 1. Female 2. Clinical diagnosis of scarring forms of alopecia or alopecia areata. 3. Clinical diagnosis on the scalp of psoriasis, scaling, fungal or bacterial infection, lesions, follicular dermatitis, lice, flees or chemical burns, unusual thinning patches, traction alopecia or trichokryptomania, trichothiodystrophy, pili annulati, monilethrix or clear signs of trichodysmorphia, poor nutrition or hygiene. 4. Damage to the skin in or around the assessment areas. 5. Scalp hair loss on the treatment area, due to disease, injury, or medical therapy. 6. History of surgical correction of hair loss on the scalp - hair transplants or hair weave. 7. Are using or have used depilatories, razors, or wax on the scalp to an extent which, in the opinion of the investigator, may interfere with the performance of the study assessments 8. In the opinion of the investigator have very little contrast between hair color and scalp that would make trichometric analyses difficult. 9. Subjects who are planning a family and becoming pregnant with their partners during the course of the study or subjects who are unwilling to use appropriate contraceptives for the duration of the study. 10. Current skin disease or conditions on the treatment area that, in the opinion of the Investigator, might put the subject at risk or interfere with the study conduct or evaluations. 11. Presence of major diseases such as diabetes, endocrine, cardiovascular, renal, or liver disease. 12. History of neurological disease (e.g. Parkinson's disease, stroke, traumatic brain injury, etc.). 13. History of blood clotting disorders or current use of coagulation-inhibiting medications including natural health products (e.g. warfarin, St. John's wort). 14. Hypertension defined as a seated resting systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg or current use of blood pressure lowering medications. 15. Recently started (<6 months) using hormone replacement therapy. 16. Use of anabolic steroids or 5-alpha reductase inhibitors in 6 months prior to the baseline visit (V2). 17. Use of any products (prescription, OTC or natural health products) or devices reported and used to promote scalp hair growth (e.g., finasteride or minoxidil, L-Tyrosine) within 90 days prior to the Baseline Visit (V2). 18. Use of any medications (including natural health products) that are known to potentially cause hair loss or affect hair growth within 30 days prior to the Baseline Visit (V2), as determined by PI. 19. History of malignancy (in past 5 years) or undergoing chemotherapy or radiation treatments. 20. A known history of autoimmune disease (e.g. HIV/AIDS, systemic lupus erythematosus, inflammatory bowel disease, alopecia areata, alopecia totalis, etc.), uncontrolled thyroid disease [hyperthyroidism, hypothyroidism; controlled will be permitted if no changes in dosage are required in the 6 months prior to screening (V1)], hepatitis C, or any other disorders that in the opinion of the investigator may interfere with the study treatment. 21. Concurrent or within 3 months of baseline (V2) use of anti- inflammatory medication, corticosteroids, or immunosuppressive drugs taken for more than 2 consecutive weeks 22. Active psychiatric disease (hospitalized within the past 12 months of Screening). 23. Evidence of hepatic or renal dysfunction as evidenced by ALT or aspartate aminotransferase (AST) being = 2 times the upper limit of normal or serum creatinine value = 1.5X the upper limit of normal or other clinically significant abnormal clinical laboratory value, such that patient would be classified as stage 3b or greater of chronic kidney failure (eGFR below 60 ml/mjn/1.73 cm2, albumin-creatinine ratio(ACR) > 3.0 mg/mmol), under treatment for uncontrolled hypertension(HT) and other factors per PI discretion. 24. History of drug or alcohol abuse in the past 12 months prior to Screening. 25. Currently consuming more than 2 standard alcoholic beverages a day. A standard alcoholic beverage is defined as 12 ounces of beer, five (5) ounces of wine, or 1.5 ounces of liquor. 26. Have a known sensitivity or allergy to any ingredients in the test products or placebo products. 27. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data. 28. Participating in or has participated in another research study within 30 days prior to screening with any investigational medical product or natural health product |
Country | Name | City | State |
---|---|---|---|
United States | Biometrix | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Arbor Life Labs |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | To evaluate Safety and Tolerability of ALRV5XR | To compare the rate of non-severe and severe adverse events in subjects treated with the ALRV5XR regimen versus placebo treatment | 24 Weeks | |
Primary | Change in terminal hair density from baseline to Week 24. | The primary outcome will determine if the increase in terminal hair count per square centimeter from baseline to Week 24 in subjects on ALRV5XR therapy is superior to placebo, at a significance level of 5% (one tail). A two-sample t test will be used to compare differences in the mean increase in terminal hair count from baseline to Week 24 between study arms. | 24 Weeks | |
Primary | The percentage change in the terminal hair regrowth from baseline to Week 24. | The primary outcome will determine if the percentage change in terminal hair count from baseline to Week 24 in subjects on ALRV5XR therapy is superior to placebo, at a significance level of 5% (one tail). A two-sample t test will be used to compare differences in the mean percentage increase in total terminal hair count from baseline to Week 24 between study arms. | 24 Weeks | |
Secondary | Change in terminal hair density from baseline | The increase in terminal hair count per square centimeter from baseline to Week 24 in subjects on ALRV5XR therapy is superior to placebo, at a significance level of 5% (one tail). A two-sample t test will be used to compare differences in the mean increase in terminal hair count from baseline to Week 12 between study arms. | Week 12 | |
Secondary | The percentage change in the terminal hair regrowth from baseline to Week 12. | The percentage change in terminal hair count | Week 12 | |
Secondary | Change from baseline in hair width. | Change from baseline in hair width, as measured by macrophotography [Time Frame: Week 12 and 24 | Week 12 and 24 | |
Secondary | Proportion of subjects achieving a =25% increase in hair number count | Proportion of subjects achieving a =25% increase in hair number count from baseline in the area being examined, as measured by macrophotography | Week 12 and 24 | |
Secondary | Proportion of subjects achieving a =50% increase in hair number count | Proportion of subjects achieving a =50% increase in hair number count from baseline in the area being examined, as measured by macrophotography | Week 12 and 24 | |
Secondary | Proportion of subjects achieving a =75% increase in hair number count | Proportion of subjects achieving a =75% increase in hair number count from baseline in the area being examined, as measured by macrophotography | Week 12 and 24 | |
Secondary | Proportion of subjects achieving a =25% increase in Severity of Alopecia Tool (SALT) scores | Proportion of subjects achieving a =25% increase in Severity of Alopecia Tool (SALT) scores from baseline. (SALT scores measure scalp hair loss for terminal hair only: 0: no hair loss; 1: 1-24% hair loss; 2: 25-49% hair loss; 3: 50-74% hair loss; 4: 75-99% hair loss, (4A: 75-90% hair loss, 4B: 91-99% hair loss); 5: 100% hair loss.) | Week 12 and 24 | |
Secondary | Proportion of subjects achieving a =50% increase in Severity of Alopecia Tool (SALT) scores | Proportion of subjects achieving a =50% increase in Severity of Alopecia Tool (SALT) scores from baseline. (SALT scores measure scalp hair loss for terminal hair only: 0: no hair loss; 1: 1-24% hair loss; 2: 25-49% hair loss; 3: 50-74% hair loss; 4: 75-99% hair loss, (4A: 75-90% hair loss, 4B: 91-99% hair loss); 5: 100% hair loss.) | Week 12 and 24 | |
Secondary | Proportion of subjects achieving a =75% increase in Severity of Alopecia Tool (SALT) scores | Proportion of subjects achieving a =75% increase in Severity of Alopecia Tool (SALT) scores from baseline. (SALT scores measure scalp hair loss for terminal hair only: 0: no hair loss; 1: 1-24% hair loss; 2: 25-49% hair loss; 3: 50-74% hair loss; 4: 75-99% hair loss, (4A: 75-90% hair loss, 4B: 91-99% hair loss); 5: 100% hair loss.) | Week 12 and 24 | |
Secondary | Change in anagen/telogen ratio | Change in anagen/telogen ratio from baseline to weeks 12 and 24 | Week 12 and 24 | |
Secondary | Dermatology Life Quality Index (DLQI) score | Dermatology Life Quality Index (DLQI) score. (0, no regrowth; 1, <25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth) | Week 12 and 24 | |
Secondary | Proportion of subjects achieving a DLQI patient global assessment score of 3 or above | Proportion of subjects achieving a DLQI patient global assessment score of 3 or above at week 24 (0, no regrowth; 1, <25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth) | Week 12 and 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02591355 -
Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment
|
N/A | |
Withdrawn |
NCT03852992 -
Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia
|
Phase 2 | |
Recruiting |
NCT06239207 -
Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Androgenetic Alopecia
|
Phase 2 | |
Completed |
NCT04945226 -
A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001
|
Phase 1/Phase 2 | |
Completed |
NCT01548066 -
The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss
|
Phase 2 | |
Completed |
NCT01437163 -
Treatment of Androgenetic Alopecia in Males and Females
|
N/A | |
Completed |
NCT01226459 -
Clinical Trial in Females for Female Pattern Hair Loss
|
Phase 3 | |
Recruiting |
NCT06118866 -
A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia
|
Phase 2 | |
Completed |
NCT06149221 -
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
|
N/A | |
Withdrawn |
NCT04882969 -
Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia
|
N/A | |
Completed |
NCT01231607 -
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
|
Phase 3 | |
Completed |
NCT04446429 -
Anti-Androgen Treatment for COVID-19
|
N/A | |
Completed |
NCT02729415 -
Point-of-Care Adipose-derived Cells for Hair Growth
|
N/A | |
Completed |
NCT02279823 -
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
|
Phase 2 | |
Not yet recruiting |
NCT01227031 -
Pharmacogenomic Study of Androgenetic Alopecia
|
N/A | |
Completed |
NCT00981461 -
Treatment of Androgenetic Alopecia in Females, 9 Beam
|
N/A | |
Completed |
NCT01451021 -
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss
|
Phase 2 | |
Completed |
NCT00151515 -
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
|
Phase 3 | |
Completed |
NCT03694067 -
Androgenetic Alopecia and the JAK-STAT Pathway
|
||
Completed |
NCT03689452 -
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
|
N/A |